PURPOSE: Indacaterol is a novel, once daily, inhaled ultra-long-acting β2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Here we compared the 24-h …

Background Indacaterol is a once-daily long-acting inhaled β 2-agonist indicated for
maintenance treatment of moderate-to-severe chronic obstructive pulmonary disease …

Abstract β2-Agonists (β2-adrenergic agonists, bronchodilatants, and sympathomimetic
drugs) are a group of drugs that are mainly used in asthma and obstructive pulmonary …

Background and objective: The efficacy and safety of indacaterol, a novel inhaled once daily
ultra long‐acting β2‐agonist was evaluated in COPD patients in six Asian countries/areas …

Onbrez Breezhaler® is a low-resistance capsule-based device that was developed to
deliver indacaterol maleate. The study was designed to investigate the effects of both …

Introduction Inhaled β-agonists have been foundational medications for maintenance COPD
management for decades. Through activation of cyclic adenosine monophosphate …

β2-adrenoceptor agonists are the mainstay for the acute symptomatic treatment of asthma
and provide effective bronchoprotection to a wide range of bronchoconstrictor agents …

An endogenous defect in β 2-adrenoceptors that results in impaired relaxation of airway
smooth muscle was originally proposed as a putative underlying cause of the asthmatic …

At present there is no cure for chronic obstructive pulmonary disease (COPD). However,
some nonpharmacologic treatments, such as rehabilitation and lung volume reduction …

Beta-2 adrenergic agonists are sympathomimetic agents that stimulate bronchodilation by
activation of adenyl cyclase to produce cyclic 3′ 5′ adenosine monophosphate (AMP) …